Should People be Micodosing Ozempic and Wegovy?  Does it Work?  What are the Risks? episode artwork

EPISODE · Mar 26, 2025 · 20 MIN

Should People be Micodosing Ozempic and Wegovy? Does it Work? What are the Risks?

from GLP-1 Tribe · host Eric Eden

There is a mega trend on social media of people discussing microdosing Ozempic, Wegovy and GLP-1 medications.  Some experts suggest microdosing is better for patients because the prescribed doses are over medicating patients. What are the pros and cons of microdosing?GLP-1 Microdosing: Trends, Evidence, and Safety ConcernsWe explore the emerging trend of microdosing GLP-1 receptor agonists, such as semaglutide and tirzepatide, which are typically prescribed for diabetes and weight loss. Microdosing refers to using significantly smaller doses than the standard therapeutic amounts, often motivated by cost savings, a desire to minimize side effects, and accessibility during shortages. While anecdotal reports suggest potential benefits, the sources emphasize the lack of scientific evidence and potential risks associated with this practice, including reduced efficacy and safety concerns, especially with compounded versions. Expert opinions and regulatory bodies generally advise caution against microdosing due to the absence of robust clinical data and the availability of approved dosing regimens. Ultimately, the texts highlight the importance of evidence-based medical guidance over unproven off-label use of these powerful medications.This is the official podcast of GLP-1 Tribe. Find out more at https://glp1tribe.com/

Episode metadata supplied by the publisher feed · Published Mar 26, 2025

Embed this episode

There is a mega trend on social media of people discussing microdosing Ozempic, Wegovy and GLP-1 medications. Some experts suggest microdosing is better for patients because the prescribed doses are over medicating patients. What are the pros and cons of microdosing? GLP-1 Microdosing: Trends, Evidence, and Safety Concerns We explore the emerging trend of microdosing GLP-1 receptor agonists, such as semaglutide and tirzepatide, which are typically prescribed for diabetes and weight los...

Distinct summary based on available episode metadata or transcript content.

NOW PLAYING

Should People be Micodosing Ozempic and Wegovy? Does it Work? What are the Risks?

0:00 20:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of GLP-1 Tribe?

This episode is 20 minutes long.

When was this GLP-1 Tribe episode published?

This episode was published on March 26, 2025.

Can I download this GLP-1 Tribe episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!